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Abstract
Background: Testicular cancer diagnosis and treatment, especially given its threat to sexuality and reproductive
health, can be distressing in the formative period of young adulthood and the majority of young survivors experience
impairing, distressing, and modifiable adverse outcomes that can persist long after medical treatment. These include
psychological distress, impairment in pursuit of life goals, persistent physical side effects, elevated risk of secondary
malignancies and chronic illness, and biobehavioral burden (e.g., enhanced inflammation, dysregulated diurnal stress
hormones). However, few targeted interventions exist to assist young survivors in renegotiating life goals and regulating
cancer-related emotions, and none focus on reducing the burden of morbidity via biobehavioral mechanisms. This paper
describes the methodology of a randomized controlled biobehavioral trial designed to investigate the feasibility and
preliminary impact of a novel intervention, Goal-focused Emotion-Regulation Therapy (GET), aimed at improving distress
symptoms, emotion regulation, goal navigation skills, and stress-sensitive biomarkers in young adult testicular cancer
patients.
Methods: Participants will be randomized to receive six sessions of GET or Individual Supportive Therapy (ISP) delivered
over 8 weeks. In addition to indicators of intervention feasibility, we will measure primary (depressive and anxiety
symptoms) and secondary (emotion regulation and goal navigation skills, career confusion) psychological outcomes prior
to (T0), immediately after (T1), and 12 weeks after (T2) intervention. Additionally, identified biomarkers will be measured at
baseline and at T2.
Discussion: GET may have the potential to improve self-regulation across biobehavioral domains, improve overall cancer
adjustment, and address the need for targeted supportive care interventions for young adult cancer survivors.
Trial registration: Clinicaltrials.gov, NCT04150848. Registered on 28 October 2019.
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Background
The development of effective interventions that prevent,
control, and eliminate physical, psychological, and be-
havioral adverse effects of cancer in young adult survi-
vors is a public health priority [1]. Testicular cancer is
the most prevalent non-skin cancer among men in late
adolescence and early adulthood, and rates of new diag-
noses have been rising over the last decade [2]. Ensuring
robust health-related quality of life is essential in this
group, as they face both psychological and physical im-
pact from potential loss of a reproductive organ and
long-term functional impacts of chemotherapy, radiation
therapy, and/or surgery [3–5]. Further, long-term seque-
lae are more severe and persistent in those receiving
chemotherapy, and include peripheral neuropathy, hear-
ing loss, hypogonadism, infertility, secondary malignan-
cies, long-term hearing loss, sexual dysfunction, and
development of cardiovascular disease [4, 6–10].
Psychosocial impact is also substantial as the preva-
lence of depressive symptoms and anxiety in testicular
cancer exceeds that in the general population [3]. Com-
mon concerns include body image disruption, social
relationships, fertility and sexual distress, masculinity
threat, work-related problems, and worry about the fu-
ture [5, 11–13] and nearly two-thirds of testicular cancer
survivors report unmet survivorship needs [13–15], most
commonly relating to supportive care, survivorship in-
formation, managing distress, fertility, relationships and
self-image, and occupational problems [14–17]. Yet
there is a paucity of psychosocial supportive cancer in-
terventions for young adults. In a systematic review,
Walker et al. [18] identified only 18 psychosocial inter-
ventions for young adult survivors, and only 8 of these
were tested in a randomized controlled trial. Also, none
of these interventions were tailored to the needs of
young men, and none targeted developmentally in-
formed processes of self-regulation.
Adjustment to challenged goals constitutes adaptive
self-regulation [19] and may be particularly critical when
cancer occurs in early adulthood [20, 21]. Cancer diag-
nosis and treatment present circumstances that chal-
lenge the achievement and pursuit of meaningful life
and developmentally timed goals (e.g., pursuit and main-
tenance of dating and sexual relationships, identification
of values-driven occupational pursuits, achievement of
independence from parents) [22, 23]. Cancer-related
goal disturbances are associated with chemotherapy re-
ceipt and a host of behavioral and psychological symp-
toms, including depression, fatigue, pain, and cognitive
complaints [24]. Concerns about the achievement of life
goals are especially distressing for adolescents and young
adult survivors [25–27], who are negotiating greater
autonomy across life domains and are oriented toward
achievement of future goals. Goal navigation skills
include the ability to identify new and existing goals;
together with emotion-regulating coping behaviors, they
have the potential to support cancer-related well-being
[28–31], and they might play a role in regulation of
stress-sensitive biobehavioral factors, including inflam-
matory and neuroendocrine processes [32, 33].
This manuscript describes the methodology of a random-
ized controlled biobehavioral pilot trial designed to investi-
gate the feasibility of Goal-focused Emotion-Regulation
Therapy (GET), a novel intervention aimed at improving
distress symptoms, self-regulation (i.e., emotion regulation
and goal navigation skills), and stress-sensitive biomarkers
in young adult testicular cancer patients with the overarch-
ing goal of establishing whether a future larger-scale trial
can and should be conducted in this manner. The interven-
tion will be administered in six sessions delivered over 8
weeks to a sample of 60 young adult (ages 18–39 years) re-
cent testicular cancer survivors. As an external pilot study,
a major focus will be on testing data collection procedures
and measurement strategies, optimizing the recruitment
plan, testing randomization, and informing appropriate
sample size estimates. Examination of the integrity and
acceptability of the study protocol will be of primary focus.
Hypotheses
We hypothesize that young adult testicular cancer survi-
vors will confirm the formative findings that the GET
intervention is feasible, tolerable, and acceptable. Fur-
thermore, we expect that, in comparison to those in In-
dividual Supportive Therapy (ISP), participants receiving
GET will have a measurable, positive improvement on
potential primary and secondary outcomes. Primary out-
comes of consideration are change in psychological dis-
tress (i.e., depressive and anxiety symptoms) from
baseline to 12 weeks post intervention and change in
systemic inflammation markers (i.e., IL-6, IL-1ra, CRP,
sTNFαRII) and salivary cortisol regulation (i.e., diurnal
cortisol slope and daily cortisol output) from baseline to
post intervention. However, results related to changes in
distress symptoms will inform sample size estimates in
future trials. Of additional focus are changes in self-
regulatory processes (i.e., emotion regulation and goal
navigation skills, career confusion) from baseline to 12
weeks post intervention.
Methods
Study design
Study goals and design were informed in part by the
SPIRIT guidelines [34], previous cancer control interven-
tion research [35, 36], and models of translational re-
search for behavioral interventions [37]. This study will
utilize a randomized, controlled, repeated-measures de-
sign to investigate the feasibility of studying GET relative
to a well-matched comparator (i.e., ISP) to improve
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identified variables in young adult testicular cancer pa-
tients. See Fig. 1.
The replication and extension of the promising and
preliminary results of our formative research (described
in the following) will contribute to satisfying the critical
need for accessible, feasible, effective, and scalable inter-
ventions for young adult survivors with the goal of
ameliorating long-term negative effects of cancer and
cancer treatment. Participants will be 60 young adults
with testicular cancer who have completed treatment
(including chemotherapy) and will be randomized 1:1
into GET or ISP using a block of 10 randomization de-
sign. A central randomization scheme will be used in
which a research recruiter will contact a central methods
center by secure computer for allocation assignment for
newly enrolled participants to maintain concealment of
the randomization sequence. The sequence will be gen-
erated by a computer randomization program.
Sample size was determined by balancing realistic re-
cruitment estimates and minimal sample requirements
for planned analyses. Informed consent will be obtained
individually following eligibility screening and prior to
data collection. The interventions will be delivered face
to face in a clinical setting. However, to enhance accessi-
bility, telephone sessions will also be possible for those
with accessibility barriers.
Participants will complete questionnaire assessments
at baseline (T0), at the completion of the last GET or
ISP session (T1), and at 12 weeks following completion
of the last GET or ISP session (T2). In addition, bio-
logical specimens will be collected at T0 and at T1.
These include the collection of plasma via venipuncture
(in the clinic) and samples of saliva (at home). Saliva is
collected over 2 days at each assessment point upon
awakening, 30 min later, 8 h later, and at bedtime [38].
Questionnaire data will be collected via an online
password-protected data collection platform. All partici-
pants will be offered $50 at each data collection point
for completion of assessments and collection of bio-
markers (and $25 without biomarker assessment).
All study procedures will be reviewed and approved by
the University of California, Irvine and Memorial Sloan
Kettering Cancer Center Institutional Review Boards.
Given the assessed low risk of trial participation, serious
adverse events and harms are not anticipated; no formal
stopping rules are designated. Likewise, a study-specific
data monitoring committee was not considered. However,
the institutional data safety board for cancer studies is
available for consultation and the investigational team will
meet weekly to monitor study progress and activities.
Participants
Participants will be young adults with a diagnosis of
testicular cancer who have completed active treatment
(surgery + chemotherapy) and present with elevated
distress and/or deficits in goal navigation skills. We will
enroll participants from the Chao Family Comprehensive
Cancer at the University of California, Irvine and
Memorial Sloan Kettering Cancer Center, and various
young adult community-based support groups or chil-
dren’s hospital settings.
Eligibility
Participants will be initially identified through electronic
medical record screening or identified by clinic personnel,
or will self-identify in response to study announcements.
Determination for study eligibility will occur via screen-
ing by a research study assistant. Participants eligible for
this study will be those who: are between the ages of 18
and 39 years at the time of consent; have a confirmed
diagnosis of testis cancer (any stage); have completed
chemotherapy for testis cancer within 2 years prior to con-
sent; have fluency in English (per self-report); and exhibit
suboptimal self-regulation, evidenced by a score of 1.8 or
below on the goal navigation scale [28] or a score of 4 or
greater on the Distress Thermometer (DT) [39].
Exclusion criteria include: lifetime history of bipolar
disorder, schizophrenia, or schizoaffective disorder (per
self-report); an active suicide plan; presence of a disorder
that compromises comprehension of assessments or in-
formed consent information (e.g., dementia); and self-
reported medical condition or medication use known to
confound measures of systemic inflammation (e.g., auto-
immune disorder, active infection; myocardial infarction
or stroke in the last 6 months; recent vaccination for
viral disease); and daily smoking [38, 40].
Participation will not require alteration to usual care
including use of any medication or psychotherapy.
Intervention conditions and delivery
Goal-Focused Emotion-Regulation Therapy
Development of GET intervention The identification
of core components and the development of the GET
intervention come from preliminary empirical work with
young adult testicular cancer survivors. First, an in-
depth interview study of a diverse sample (N = 21; 48%
ethnic minority) of young adult survivors of testicular
cancer [41] revealed that young men perceive that life
goals are an important aspect of adapting to testicular
cancer, and identified goal and values clarification,
engagement and disengagement from life goals, and the
ability to express and process emotional responses to
disrupted goals among critical self-regulation skills
regarding behavioral and emotional responses to cancer-
related stressors. Second, they identified a preference for
action orientation, positivity, achievement, and practical
realism. This included an inclination toward the use of
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an active, approach-oriented stance to pursuing prior
goals and/or reengaging with new goals after cancer.
Third, findings suggested that when goal navigation cap-
acity was low or impaired, young men were less likely to
benefit from their efforts at approach-oriented coping.
In a follow-up observational study of the same popu-
lation (N = 171), Hoyt et al. [28] identified measurable
goal-related processes including “goal navigation”, or
the capacity to identify and pursue valued life goals.
Goal navigation demonstrated cross-sectional associa-
tions with aspects of cancer-related adjustment. In re-
gression analyses controlling for age and time since
diagnosis, goal navigation was positively associated with
emotional (B = 0.35, p < 0.001), social (B = 0.24,
p < 0.01), and functional (B = 0.28, p < 0.001) well-
being [41]. Further, a theoretical model of goal naviga-
tion using a self-regulation framework was identified
and tested [42]. Goal navigation skills were negatively
correlated with depressive symptoms (r = − 0.41, p <
0.01) and positively correlated with physical functioning
(r = 0.28, p < 0.01), and these were mediated by posses-
sing a sense of meaning in goal pursuit (indirect effects:
depressive symptoms (r = − 0.50, p < 0.05), physical
health (r = 0.34, p < 0.05)) and emotion regulation skill
(indirect effects: depressive symptoms (r = − 0.08, p <
0.05), physical health (r = 0.11, p < 0.05)).
In a follow-up, at-home monitoring study (unpub-
lished data) to examine associations of goal navigation
skill, emotion regulation, and salivary markers of diurnal
cortisol and α-amylase, the use of emotion regulation
skills and salivary measures were collected daily for 2
days. Low levels of goal navigation capacity were signifi-
cantly associated with greater use of less constructive
emotion regulation strategies and higher daily salivary
cortisol output (area under the curve). Poor self-
regulation skills underscore dysregulation of biological
processes with strong potential to lead to declines in
physical health and mood.
Taken together, these findings underscored develop-
ment of GET and an initial intervention manual which
was tested to establish the feasibility and acceptability
for the patient population. This included initial patient
focus group interviews, as well as a series of individual
patient interviews to gain feedback into session content,
intervention length and format, and structured at-home
components. A revised manual emerged that, based on
findings, included more “normalization of experience”,
opportunities to address cancer-specific topics (e.g.,
cancer-related disclosure, self-care after cancer), and
bolstering of emotion regulation skill-building.
Next, the revised intervention was pilot tested with six
young adult testicular cancer patients to assess tolerability,
acceptability, adherence, and retention. This was done
through examination of treatment completion and
engagement with at-home exercises as well as in-
depth post-participation interviews. Supporting toler-
ability and acceptability, all six participants completed
all study sessions with no adverse events. Also, partic-
ipants’ engagement with assigned at-home exercises
were coded as “attempted/not attempted” to inform
adherence. Moderate adherence was observed with
78% of assigned activities attempted. Interview tran-
scripts were analyzed with a targeted inductive pro-
cedure of thematic analysis. This involved thorough
reading and review of transcripts, synthesis of key
conceptual findings, and the generation of descriptive
conclusions. Conclusions identified eagerness for a
survivorship intervention, affirmation of the import-
ance of the identified intervention targets, satisfaction
with the intervention length and depth, and desire for
study interventionists to challenge participants to “go
deeper” in the process of identifying and processing
emotions. Participants also identified the desire to
hear more perspectives from other testicular cancer
survivors. Finally, the manual was further refined
based on interview findings. This included the inclu-
sion of patient quotes in study participant hand-outs.
GET intervention components GET is a six-session
intervention delivered over 8 weeks to enhance self-
regulation through improved goal navigation skills,
improved sense of meaning and purpose, and better
ability to regulate specific emotional responses. GET
draws heavily from the principles of Hope Therapy
[43], with an emphasis on goal navigation skill-
building. Components of Hope Therapy have been
used successfully in cancer survivorship interventions
[44]. This includes work on goal-setting with a focus
on assessing progress toward achieving specific, realis-
tic, and measurable goals. Patients identify value-
derived goals (i.e., goals for the most important
domains of one’s life) and ones sufficiently important
to sustain movement toward them in the short-term
future. They discuss their goal possibilities, providing
a forum to ensure that goals are manageable and con-
sistent with identified values. Patients learn strategies
to refine their goals (e.g., approaching goals rather
than avoiding obstacles, defining markers of progress),
generate pathways to goals, and address potential ob-
stacles and blockages. Additionally, goals provided the
context for demonstrations of agentic thinking (e.g., I
will be able to do this) and interventions to increase
agentic thinking. Specific attention is given to career/
education-related goals. Emotion regulation compo-
nents include basic cognitive restructuring skills, cog-
nitive distancing, and coping efficacy skills (matching
the correct coping skill to specific circumstances) (see
Table 1).
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Individual Supportive Psychotherapy
ISP will be utilized as the comparison treatment condition
in this study. ISP is one of the predominant approaches to
community-based supportive care in psychosocial oncol-
ogy. In this study, ISP is adapted from the Supportive
Group Psychotherapy manualized intervention [45], and
subsequently adapted further for use in our pilot work for
young adult testicular cancer patients. This intervention
includes six sessions of Individual Supportive Psychother-
apy utilizing an approach based on models described by
Rogers [46, 47] and Block [48], including components of
genuineness, unconditional positive regard, and empathic
understanding through reassurance, explanation, guid-
ance, suggestion, encouragement, affecting changes in
patient’s environment, and permission for catharsis [48].
ISP also emphasizes maintaining focus on the cancer ex-
perience, supporting participants in the “here and now”,
fostering expression of emotion and discussion of difficult
topics, and creating a sense of being understood [45]. The
manual offers instructions on how to avoid therapeutic
techniques associated with other treatment modalities
(e.g., CBT, interpersonal psychotherapy).
Intervention delivery
GET and ISP will be delivered by at least a master’s-level
mental health clinician interventionist who will receive
intensive training prior to delivering the intervention
and regular supervision after each session. All interven-
tionists will be male. Therapists without prior GET
experience will conduct one or two training cases with
patients not enrolled in the proposed study. Participants
consented as training cases will not be randomized and
will not complete any formal assessments.
Sessions will be audio recorded so that treatment fidel-
ity can be regularly monitored and independently rated
by trained research assistants.
Participants will be permitted to continue to see any
outside mental health professionals during the trial. In
these instances, outside interventions will be docu-
mented and controlled for during data analysis.
Data collection and measurement
Data collection
Data will be collected at each identified time point and dur-
ing the eligibility screening process. A research study assist-
ant, blinded to the study objectives and randomization,
administers the screening questionnaire verbally. Baseline
and T1 data collection will be completed during an in-
person meeting where they complete questionnaires via
computer and provide a blood sample. Saliva will be
collected over 2 days at home in close proximity to these
data collection points. Participants can complete T2 ques-
tionnaires remotely by computer. Following study comple-
tion, we will conduct a medical record review. Finally, a
subset of GET-assigned participants (n = 6) will be asked to
participate in a qualitative exit interview to gather subject-
ive experiences of participation. See Table 2 for the data
collection plan.
Measures
Screening measures Two measures are used in partici-
pant screening, as described earlier: the Distress Therm-
ometer (DT) and the Cancer Assessment for Young
Adults (CAYA-T; Goal Navigation Skill subscale). The
DT [39] is a single-item visual analog scale used to
screen cancer patients and ICs for psychological distress
with a 0–10 range accompanied by a 34-item problem
checklist [49]. Extensive research has identified a score
of 4 or greater for identifying clinically significant dis-
tress [50, 51].
Table 1 GET session guide
Session Session focus
1 Review of cancer-related experiences and influences on
goal pursuits; psychoeducation regarding emotions, skills,
and values
2 Values clarifications and emotional awareness
3 Achievability of goals, cognitive skills training
4 Goal pathway mapping, navigating blocked goals and
re-directing energy
5 Goal motivation and agentic actions, self-care behavior
6 Goal pursuits moving forward
GET Goal-Focused Emotion-Regulation Therapy
Fig. 1 Study schematic. GET Goal-Focused Emotion-Regulation Therapy, ISP Individual Supportive Psychotherapy, R randomization, Sn session
number, T0 baseline, T1 post Intervention, T2 12-week follow-up
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Goal navigation skill is measured by the goal naviga-
tion scale of the CAYA-T [28]. The CAYA-T has been
validated on a sample of young adult men with testicular
cancer and has demonstrated good psychometric prop-
erties in this population.
Depression and anxiety symptoms Depression and
anxiety will be assessed using the Hospital Anxiety and
Depression Scale (HADS) [52], a 14-item self-rated
questionnaire of overall psychological distress, well
tested in cancer populations [53].
Emotion regulation Emotion regulation skills will be
measured by the Emotion Regulation Questionnaire
(ERQ) [54]. The ERQ is a widely used 10-item scale de-
signed to measure respondents’ tendency to regulate
their emotions in two ways: cognitive reappraisal and ex-
pressive suppression. Respondents answer each item on
a 7-point scale ranging from 1 (strongly disagree) to 7
(strongly agree).
Goal navigation Goal navigation skill is measured by
the goal navigation scale of the CAYA-T, as already de-
scribed. In addition, goal regulation capacity will be
measured by agency and pathways. The Hope Scale [55]
is a 12-item measure of a respondent’s level of hope. In
particular, the scale is divided into two subscales that
comprise Snyder’s cognitive model of hope: agency (i.e.,
goal-directed energy) and pathways (i.e., planning to ac-
complish goals).
Career confusion Career confusion will be measured
with the Career Thoughts Inventory (CTI) [56]. The
CTI is a 48-item measure that is designed to assess car-
eer navigation difficulty and is normed on adult popula-
tions. The CTI yields a total score as well as scores on
three construct scales: decision-making confusion, com-
mitment anxiety, and external conflict.
Demographic and clinical information Demographic
information, past/current psychosocial service use,
support needs, intervention preferences, and perceived
barriers are assessed through Likert-scale ratings and
open-ended items. Clinical information will also be
assessed via medical record review and via self-report. In
addition, we will thoroughly assess for medical comor-
bidities and physical health symptoms.
Biological assessments
Inflammatory markers We will focus on five inflamma-
tory biomarkers that have proinflammatory function, are
associated with distress symptoms, and/or have angio-
genic properties: IL-6, IL-1RA, CRP, sTNFrR2, and
VEGF. Blood samples for circulating inflammatory
markers will be collected between the hours of 8 a.m.
Table 2 Data collection scheme
Enrollment Assessment Close-out
Timepoint Pre T0 T0 Post baseline T1 T2 Post T2 Chart review
Screening
Eligibility screen X
Informed consent X
Allocation X
Interventions
GET
ISP
Assessments
Hospital Anxiety and Depression Scale (HADS) X X X
Goal Navigation (CAYA-T) X X X
Emotion Regulation Questionnaire (ERQ) X X X
Career Thoughts Inventory (CTI) X X X
Blood draw X X
At-home saliva sampling X X
Demographics X
Semi-structured interview X
Medical chart review X
CAYAQ-T Cancer Assessment for Young Adults—Testicular, GET Goal-Focused Emotion-Regulation Therapy, ISP Individual Supportive Psychotherapy, T0 baseline,
T1 post Intervention, T2 12-week follow-up
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and 4 p.m. by a trained phlebotomist by venipuncture
into EDTA heparinized tubes, placed on ice, centrifuged
for acquisition of plasma within 30min, and stored at −
80 °C for subsequent batch testing. Plasma levels of
identified markers will be determined by enzyme-linked
immunosorbent assay according to the assay manufac-
turer’s protocols. CRP will be determined by a high-
sensitivity enzyme-linked immunosorbent assay accord-
ing to the assay manufacturer’s protocol. All samples will
be run in duplicate, and assays will be repeated on two
separate days for sTNFr and IL-6; intraassay and interas-
say mean levels will be used in all analyses.
Diurnal salivary stress biomarkers We will focus on
two salivary stress biomarkers. These include salivary
cortisol, as a downstream marker of HPA activity, and
salivary α-amylase (sAA), as a proxy measure of SAM
activation; they can be measured concomitantly [57] and
together offer a comprehensive view of physiological
stress, as differing diagnostic and treatment effects have
been observed between these markers [58]. Both salivary
cortisol and sAA follow a distinct diurnal rhythm: corti-
sol levels peak approximately 30 min after awakening
and decrease throughout the day, whereas sAA has a
pronounced decline after awakening followed by an in-
crease across the day [57].
Diurnal rhythm in salivary markers will be measured
over 2 days at baseline and post intervention. Partici-
pants will collect saliva samples in their natural environ-
ment upon awakening, 30 min later, 8 h later, and at
bedtime as recommended by Nicolson [38]. Participants
will be instructed to go about their normal daily activ-
ities on the days of data collection and will complete a
diary to assess relevant health behaviors (e.g., caffeine
use). To avoid sample contamination, they will be
instructed to avoid brushing their teeth, eating, or drink-
ing within 20min before sampling. Participants will be
instructed to keep samples refrigerated prior to return-
ing them to the research laboratory and returned saliv-
ettes will be stored in a freezer at – 80 °C until analyzed.
After data collection is complete, salivary markers will
be analyzed with a time-resolved fluorescence immuno-
assay. Several indices will be computed including diurnal
slope, area under the daily curve, cortisol awakening re-
sponse, and total daily cortisol output.
Evaluation data
Qualitative interview Six participants who complete
the GET sessions will be invited to complete a semi-
structured qualitative interview, using a semi-structured
interview guide. Consecutive participants completing
GET will be offered participation in the interviews until
six interviews are completed. The interview will focus on
understanding feasibility, tolerability, and acceptability of
GET and overall trial participation from the patient’s
perspective. Through the interviews, participants will
provide information about their experience of participat-
ing in GET, including challenges to their participation
and elements that they found most and least appealing.
Qualitative methods will be employed to elicit and evalu-
ate participant responses to the semi-structured inter-
view. The interview transcripts will be analyzed with a
targeted inductive procedure of qualitative thematic text
analysis [59]. This process will involve thorough reading
and review of transcripts by an analysis team; synthesiz-
ing key conceptual findings of each transcript; identify-
ing key conceptual findings across all transcripts; and
generating descriptive and interpretive themes for the
entire data set.
Patient satisfaction A 16-item questionnaire adminis-
tered after the last session was adapted from a measure
used in currently/past federally funded intervention
studies. Items query subjects’ responses to the various
components of the intervention (e.g., content, timing,
and length of sessions), and will be used for intervention
modification.
Descriptive data
We will use descriptive statistics to summarize multiple
aspects of study feasibility, including acceptability (per-
centage of approached and eligible men who consent to
the study), tolerability (percentage of consented and en-
rolled men who complete the study in both arms), and
adherence (descriptive statistics summarizing the rate of
patients completing the scheduled sessions for both
arms).
Data analysis
Standard descriptive statistics will be used to report
baseline participant characteristics by condition. For
continuous variables with markedly non-normal or
skewed distributions, appropriate transformations may
be required, such as natural logarithms, and will be ap-
plied as necessary and appropriate. We will perform ana-
lysis according to the intention-to-treat principle (i.e.,
participants will be analyzed according to the treatment
group to which they will be randomly allocated regard-
less of dropout or treatment adherence status).
Change from baseline will be calculated across vari-
ables. Follow-up scores on the identified variables will be
compared between study conditions (adjusting for base-
line), via repeated-measures analysis of covariance
(ANCOVA). We will also reference established cutoff
values for clinically meaningful differences for scores on
the HADS to identify ranges and patterns of change.
Mixed-effects models will be used to model the scores
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over time for each group. Time since diagnosis, educa-
tion, marital status, medical comorbidities, and age will
be examined as potential covariates to model.
Discussion
This trial will evaluate the feasibility of an individual bio-
behavioral intervention targeted to the needs of young
adult men treated for testicular cancer. There is signifi-
cant need for appropriate behavioral intervention in
order to decrease the psychological, physical, and social
toll of diagnosis and treatment. Meeting these needs is
challenging, as men (particularly younger men) tend not
to seek professional help for distress [60]. In fact, there
is increasing evidence that men are reluctant to seek
professional help due to “traditional” masculine attitudes
[61], highlighting the need to develop interventions that
are both accessible and acceptable to men. A meta-
synthesis of qualitative studies [62] investigating the ac-
cessibility and acceptability of self-management support
interventions (both online and offline) for men with
long-term conditions, including cancer, found that self-
regulation interventions may be particularly more ac-
ceptable to men, as they enable the men to take control
over managing their distress (promoting self-sufficiency
and independence).
A central target of the developed intervention is goal
navigation skills. These include the ability to identify new
and existing goals, which serves to support cancer-related
well-being [28]. A second targeted self-regulatory process is
emotion regulation. Indeed, difficulty regulating emotions
is common across psychological disorders [63]. Emotion
regulation involves generating emotional responses, as well
as modulating the manner in which one alters, experiences,
and communicates such responses [64].
Specific limitations to this study should be acknowl-
edged. It is possible that elements of GET could be
accessed in a supportive listening approach. However,
our pilot work and our use of ISP in other trials suggest
this possibility is limited. Further, our fidelity coding
plan includes assessing each session for any such con-
tamination. It is also notable that the target patient
group is a relatively small patient population. However,
preliminary testing of the recruitment plan and a clinical
data review suggest the likelihood of success in obtaining
the sample. Also, a portion of the success of the study
will rely on proper sample collection at home. Use of
online and smart technologies may be helpful in this re-
gard. A demonstration video of proper saliva collection
and sample handling will be made available to all partici-
pates. Likewise, new smartphone applications have been
designed to specifically record the timing and compli-
ance of at-home sampling. Finally, it should also be
acknowledged that the distress screening measure is
different from the depression and anxiety outcome
measure. This strategy proved effective in pilot work.
The use of the DT as a screening tool allowed for poten-
tial participants to identify diffuse experiences of dis-
tress, rather than endorsement of specific depressive
symptoms.
Dependent on our findings, future directions will in-
clude a larger efficacy trial, with a focus on examining
impact on longer-term (and late) adverse effects by in-
cluding a longer-term follow-up period, recognizing the
potential future physical and psychological vulnerabil-
ities of this population. An additional future priority will
be to test the intervention across cancer types. It will
also be important to identify differential effects of each
intervention component, and determination of who re-
sponds best to each component for better optimization.
Finally, future studies will also evaluate the feasibility,
acceptability, and efficacy of the delivery of GET via
mobile application or telehealth modalities.
Findings from this study will be reported in line with
CONSORT standards for reporting pilot and feasibility
trials [65, 66], and will inform the possibility of a future
larger-scale trial which has potential to impact long-
term cancer survivorship in a population largely under-
served by typical cancer survivorship care. Aligned with
recommended goals of pilot studies [67], the primary
conclusions of this study will be related to decisions on
whether to proceed and how to proceed with a future ef-
ficacy trial. Observations of change will be treated with
caution and considered preliminary. Study results as
they pertain to the aims of this pilot study will be com-
municated to relevant scientific and clinical communi-
ties via peer-reviewed publications, scientific and clinical
conference presentations, and report writing for lay au-
diences. In addition, if our biobehavioral approach is
supported, it will inform the biological pathways and risk
factors that influence the negative adverse impacts of
cancer and cancer treatment over the long term.
Trial status
This trial was initiated in January 2017. Recruitment is
ongoing and expected to complete by October 2020.
This protocol is version 2.
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